Program XIX world congress Amsterdam 2017

As a member of ISSTD you have acces to the presentations, abstracts and poster presentation abstrects. Click on the name of the presentation for the abstrect or press (PPT) for the presentation in PDF. 

Thursday 21 September, 2017 - 
NKI/AVL, Plesmanlaan 121, Amsterdam

  Nominating comittee meets online
08:30-09:00 ISSTD executive registration and welcome
09:00-11:00 ISSTD executive meeting
10:00-11:00 EOTTD working party registration and welcome
11:00-13:00 EOTTD working parties
13:00-14:00 Lunch
14:00 Departure to Boom Chicago Theater (by bus)

Thursday 21 September, 2017 - Boom Chicago Theater, Rozengracht 117,  Amsterdam

14:30-15:30  Registration and welcoming participants & partners with coffee/tea
15:30-16:30 Key note speakers

Welcome by ISSTD President Elect Leon Massuger in temporarily absence of ISSTD President Xiang Yang

Debate "to dose high or not to dose high, that's the question"
Michael Seckl (PPT contra) & Anneke Westermann (PPT pro)

Life Lines
Eva van Kempen - PPT

Medicine and Art in Amsterdam
Hans Trum 

16:30-17:00 Break
17:00-18:00 Show Boom Chicago
18:00-18:30 Drinks
18:30 End – Evening on own
19:00 Executive dinner (for invited guests only)

 Friday 22 September, 2017 - Rode Hoed, Keizersgracht 102, Amsterdam

08:30-09:00 Registration and welcoming participants

Plenary session organized by the Turkish Working Party on GTD
Chairs: Mehmet Harma & Sinan Ozalp

Epidemiological status of GTD in Turkey: experiences from a transition zone -Middle East to Western World
Sinan Ozalp - PPT

Oxidative stress and hydatidiform mole
Muge Harma - PPT

The effects of different chemotherapeutic agents on the JAR and JEG-3 human choriocarcinoma cell line models 
Mehmet Harma - PPT

Chairs: Ross Berkowitz & Raymond Osborne

Significance of Chest Computed Tomography in the Clinical Outcome of Patients with Low-Risk Gestational Trophoblastic Neoplasia
Maria Billones-De Ramos - PPT

Should CT scan be recommended for the primary imaging evaluation in the FIGO staging of gestational trophoblastic neoplasm patients?
Yu Cheng - PPT

Uterine artery pulsatility index plus serum BMP-9 improves prediction of methotrexate resistance in Gestational Trophoblastic Neoplasia
Kevin Elias - PPT
10:30-11:00 Coffee Break

Worldwide referral centers & registries
Chairs: Fay Cagayan & Rafael Cortes-Charry

Current Management and treatment outcomes of Gestational Trophoblastic Neoplasia at a Philippine Tertiary Government Hospital
Maria Cagayan - PPT

Current survival rate of 651 post-molar gestational trophoblastic neoplasia (PMGTN) cases treated between 2009-2016 in a national reference Centre
Rafael Cortes-Charry - PPT

The Danish Trophoblast Database
Lone Sunde - PPT

Clinical epidemiology in gestational trophoblastic neoplasia in West Java, Indonesia
Herman Susanto - PPT

The Belgian Registry for gestational trophoblastic diseases: curative effect of a second curettage
Aleide Vandewal - PPT

Incidence Change of Hydatidiform Mole in Asia and Middle East: Important Role for Sociological Factors
Xingran Wang - PPT
12:10-12:40 Poster Tour I
12:40-13:30 Lunch

Genetics & Molecular pathways and clinical implications
Chairs: Vilmos Fulop & Annie Cheung

PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes
Pierre Bolze - PPT

Novel cases of recurrent hydatidiform mole expand the spectrum of familial recurrent hydatidiform mole
Rosemary Fisher - PPT

Targeted Genomic Profiling and PD-L1 expression in Epithelioid Trophoblastic Tumors and Placental Site Trophoblastic Tumors
Neil Horowitz - PPT

miRNA-seq reveals distinct miRNA profiles between regressing and progressing cases of complete mole
Lawrence Lin - PPT

Genotyping of possible hydatidiform moles may lead to incidental findings of abnormalities with implications for future pregnancies
Shyama Mohan - PPT

The Genetics of Recurrent Hydatidiform Moles: New Findings and Lessons from the analysis of 111 patients
Rima Slim - PPT
14:30-15:00 Tea Break

Molar Pregnancies - organized by WOG
(gynecologic oncology workgroup The Netherlands)
Chairs: Marianne ten Kate-Booij & Leon Massuger

Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide data-set
Yalck Eysbouts - PPT

Online patient information about Gestational Trophoblastic Diseases & the TROPHY-study
Minke Frijstein - PPT

New Dutch regression curve
Teun van Herwaarden - PPT

Early prediction of post-molar gestational trophoblastic neoplasia with the use of a single serum human chorionic gonadotropin measurement
Yalck Eysbouts 
16:00-16:15 Discussion

Chairs: Sophie Patrier & Frederic Goffin

Clinical outcomes of partial hydatidiform mole in a post- p57 era
Michelle Davis - PPT

Central pathology review for gestational trophoblastic diseases: the experience of the Belgian registry in 344 patients
Frederic Goffin - PPT

N-acetylglucosaminyltransferase IVa promotes invasion of choriocarcinoma
Kimihiro Nishino - PPT

Intraplacental choriocarcinoma arising during a normal pregnancy, in a patient with a previous complete mole: Identification of the causative pregnancy by molecular genotyping
Sophie Patrier - PPT
16:55-17:05 Discussion
17:05 End – Evening on own


Saturday 23 September, 2017 - Rode Hoed

08:30-09:00  Welcoming participants

Plenary session organized by EOTTD
Chairs: John Tidy & Giorgia Mangili

Immunologic Pathways and treatment in GTN 
Michael Seckl - PTT

Is chemotherapy always needed for choriocarcinoma management?
Pierre-Adrien Bolze - PTT

Report on EOTTD outreach/teaching sessions
Leon Massuger - PTT

Setting up an Irish GTD Center 
John Coulter - PPT

Does body surface area effect the response to treatment with flat-fixed dose intramuscular methotrexate for low risk Gestational Trophoblastic Neoplasia (GTN)?
Kaveetha Kandiah - PPT
10:15-10:45 Break

Chairs: Fred Sweep & Richard Harvey

Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Antonio Braga - PPT

Persistent Real Low-level of Human Chorionic Gonadotropin: Clinical Analysis and Treatment Recommendation
Fengzhi Feng - PPT

Does post-pregnancy human chorionic gonadotrophin (hCG) testing identify patients with recurrent gestational trophoblastic disease (GTD)? A national retrospective health care evaluation
Kate Earp - PPT

Molar disease
Chairs: Andrea Garret & Greg Robertson

One year of short partial mole follow-up in a UK GTD centre – who did we review and what difference did it make?
Annie Hills - PPT

Systematic histology review of 1521 cases referred to tertiary referral centre- a changing pattern?
Baljeet Kaur - PPT

Hydatidiform mole: Accuracy of the Danish National Patient Registry, the Danish Cancer Registry, and the Danish Pathology Registry 1999-2010
Helle Lund - PPT

WHO Prognostic classification system for Gestational Trophoblastic Neoplasia – can we do better?
Victoria Parker - represented by Matt Winter - PPT

The influence and evaluation of lung metastasis on the outcome of patients in gestational trophoblastic neoplasia - a 10 years' study in a single institute 
Hailin Yu - PPT
12:15-12:25 Discussion
12:25-13:30 Lunch
13:30-14:00 Poster Tour II

Low-risk GTN
Chairs: Francois Golfier & Antonio Braga

Second curettage in low risk gestational trophoblastic neoplasia
Ray Osborne - PPT

The Impact of Uterine Re-curettage on the Number of Chemotherapy Courses in Treatment of Post Molar Gestational Trophoblastic Neoplasia. A Randomized – Controlled Study
Reda Hemida - PPT

Efficacy and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience
Izildinha Maesta - PPT

Prevalence and factors associated with hydatidiform mole among patients undergoing uterine evacuation 
Olivier Mulisya - PPT

TA Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Treatment of Low Risk Gestational Trophoblastic Neoplasia
Julian Schink - PPT

Can increasing the hCG cut-off from 300 IU/L to 1000 IU/L for starting actinomycin D (ActD) in low risk (LR) patients with post-molar gestational trophoblastic neoplasia (GTN) developing resistance to methotrexate and folinic acid (MTX/FA), spare more women multi-agent chemotherapy without compromising outcomes?
Michael Seckl - PPT
15:30-15:45 Discussion
15:45 End
16:00-17:00 Boattour through Amsterdam
18:15-22:30 Social evening and dinner in Koepelkerk


Sunday 24 September, 2017 - Rode Hoed

08:30 Welcoming participants

High-risk GTN
Chairs: Hideo Matsui & Michael Seckl

Paclitaxel and Etoposide alternating with Paclitaxel and Cisplatin (TE/TP) as a salvage chemotherapy for gestational trophoblastic neoplasia (GTN) relapsed or refractory to Etoposide, Methotrexate and Actinomycin D alternating with Cyclophosphamide and Vincristine (EMA/CO)
Preetha Aravind - PTT

The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia
Minke Frijstein by Michael Seckl - PTT

Gestational trophoblastic neoplasia with brain metastasis at diagnosis: a retrospective cohort study
François Golfier - PTT

Use of Granulocyte Colony Stimulating Factors (G-CSFs) with Multiagent Chemotherapy for High-Risk Gestational Trophoblastic Neoplasia (GTN) Decreases Neutropenic Complications and Treatment Delays
John Lurain - PTT

The role of Central Nervous System Chemoprophylaxis in the treatment of Gestational Trophoblastic Neoplasia: a single center experience
Naveed Sarwar - PTT

Comparison of toxicities between MEA and EMA-CO regimens as first line treatment of high-risk GTN
Kam Singh - PPT

Choriocarcinoma Associated with Term Pregnancy
Anna Strohl - PPT

Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study
Yang Xiang - PPT

Efficacy and side effects of FAEV regimen and EMA/CO regimen as primary treatment for high-risk gestational trophoblastic neoplasia
Jun Zhao - PPT
10:30-11:00 Coffee break

Chairs: Matt Winter & Hextan Ngan

Identification of new prognostic factors for placental-site and epithelioid trophoblastic tumours (PSTT/ETT): platinum-based intensive chemotherapy improves survival in poor risk patients
Fieke Froeling by Michael Seckl - PPT

Single center experience in the management of Epithelioid Trophoblastic Tumor
Lawrence Lin - PPT

The Demographics, Natural History and Treatment Outcome of Gestational Choriocarcinoma
Philip Savage - PPT

Surgery and Platinum/Etoposide-Based Chemotherapy for the Treatment of Epithelioid Trophoblastic Tumor
Janelle Sobecki-Rausch - PPT

Ultra high-risk gestational trophoblastic neoplasia (UHR GTN) and placental site/epithelioid trophoblastic tumours (PSTT/ETTs): an international collaborative database project
Matt Winter - PPT
12:00-12:30 Poster Tour III
12:30-13:30 Lunch

Social aspects of GTN
Chairs: John Lurain & Leon Massuger

Provincial GTD / GTN Registry: Patients and Healthcare Providers’ Satisfaction
It is insufficient to simply inform patients with trophoblastic diseases: they want to be accompanied
Magali Breguet - PPT

Gestational Trophoblastic Disease Electronic Consults: What do Patients and Physicians Want to Know?
Roni Nitecki - PPT

The Role of Nurse Clinicians and Advanced Practice Providers in the Management of Supportive Oncology Needs and Treatment-Related Side Effects for Women with Gestational Trophoblastic Neoplasia (GTN)
Karen Novak - PPT

Gestational trophoblastic desease: reproductive performance on following pregnancy - an 19 years analysis in a reference center
Elza Uberti - PPT
14:20-15:40 Treatment
Chairs: John Coulter & Xiang Yiang

Efficacy and toxicity of second-line 5-day dactinomycin in methoresistant GTN patients
Pierre-Adrien Bolze - PPT

Cyclin dependent kinases 4 and 6 (CDK4/6) as a potential new therapeutic target in drug-resistant gestational trophoblastic neoplasia (GTN)
Marina Georgiou - PPT

Pembrolizumab induces long term complete remission of chemotherapy resistant gestational trophoblastic neoplasia (GTN)
Ehsan Ghorani - PPT

Decentralized treatment for post-molar gestational trophoblastic neoplasia (PMGTN) is associated with increased lines of chemotherapy and longer time to remission
Whitfield Growdon by Elisabeth Diver - PPT
15:00-15:30 Tea break

The Efficacy and Safety of Different Chemotherapy Regimens in Low-risk Gestational Trophoblastic Neoplasia: A Network Meta-analysis 
Jun Li - PPT

First-line hysterectomy for women no longer wishing to conceive with low-risk gestational trophoblastic neoplasia
Jérôme Massardier - PPT

Gestational Trophoblastic Neoplasia Located in the Cesarean Scar: A review of 31 cases and their implications for diagnosis and treatments
Junjun Yang - PPT

TROPHIMMUN, a phase II trial of the anti-PDL1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia patients: preliminary results
Benoit You 
16:10-16:30 General Assembly
16:30-17:00 Closing Ceremony and Awards 
17:00 End of XIX World Congress of Gestational Trophoblastic Diseases